From: Critical appraisal of the role of serum albumin in cardiovascular disease
Study | Year | Number | Characteristics of patients | Albumin cut-off value | Outcomes |
---|---|---|---|---|---|
Coronary artery disease (CAD) | |||||
 Hartopo et al. [42] | 2010 | 82 | ACS | < 3.5 g/dL | ↑In-hospital adverse eventa |
 Bhamidipati et al. [43] | 2011 | 2794 | CAD undergoing CABG | < 3 g/dL | ↑Mortality and post-operative complications |
 Oduncu et al. [39] | 2013 | 1706 | STEMI undergoing primary PCI | < 3.5 g/dlL | ↑3.5-year all mortality and advanced HF |
 Sujino et al. [40] | 2015 | 62 | Age ≧ 85 years, STEMI | Continuous variable | ↑In-hospital mortality |
 Murat et al. [46] | 2015 | 890 | ACS undergoing PCI | Continuous variable | ↑Contrast induced acute kidney injury and in-hospital mortality |
 Kurtul et al. [47] | 2015 | 536 | STEMI undergoing PCI | < 3.75 g/dL | ↑Risk of no-reflow after PCI |
 Plakht et al. [41] | 2016 | 8750 | AMI | categorize albumin level by 3.4, 3.7, 3.9, 4.1 g/dL | ↑10-year all mortality |
 Kurtul et al. [45] | 2016 | 1303 | ACS undergoing coronary angiography | < 3.3 g/dL | ↑SYNTAX score and in-hospital mortality |
 Celik et al. [48] | 2016 | 341 | PCI with a BMS | < 3.81 g/dL | ↑Risk of in-stent restenosis after PCI |
 Wada et al. [44] | 2017 | 2860 | CAD undergoing PCI | 3.8 g/dL; 4.1 g/dL | ↑MACE and 10-year all mortalityb |
 Chien et al. [49] | 2017 | 734 | Stable CAD | < 3.5 g/dL | ↑1.5-year MACE and mortalityc |
Ischemic stroke | |||||
 Gillum et al. [50] | 1994 | 4897 | White men aged 65–74 years; Blacks aged 45–74 years | < 4.2 vs > 4.4 g/dL | ↑14-year stroke incidence and stroke mortality |
 Dziedzic et al. [53] | 2004 | 759 | Acute ischemic stroke | < 4.9 g/dL | Poor 3-month neurologic outcomed |
 Hostmark et al. [52] | 2006 | 5071 | 30–75 years | < 4.7 g/dL | ↑(self-reported) Stroke incidence |
 Xu et al. [51] | 2014 | 2986 | >40 years old | < 4.2 vs > 4.6 g/dL | ↑12-year stroke incidence |
Peripheral Arterial Disease (PAD) | |||||
 O’Hare et al. [56] | 2002 | 14,427 | Hemodialysis patients | Continuous variable | ↑PAD incidence |
 Beddhu et al. [57] | 2002 | 1411 | Hemodialysis patients | < 3.6 g/dL | ↑PAD incidence |
 Schillinger et al. [60] | 2004 | 702 | PAD patients with less than 2 traditional risk factors | < 3.85 g/dL | ↑1-year MACEf |
 Ishii et al. [59] | 2013 | 450 | Hemodialysis patients undergoing endovascular therapy | < 3.6 g/dL | ↑3-year major adverse limb evente |
 Tsai et al. [58] | 2015 | 444 | Hemodialysis patients | Continuous variable | ↑4-year all or CV mortality |
Heart failure (HF) | |||||
 Horwich et al. [61] | 2008 | 1726 | Systolic HF | ≤ 3.4 g/dl | ↑1- and 5- year all mortality ↑Urgent heart transplant |
 Kinugasa et al. [63] | 2009 | 349 | Age ≧ 65, Acute HF | < 3.2 g/dL | ↑In-hospital mortality |
 Uthamalingam et al. [64] | 2010 | 438 | Acute, systolic HF | < 3.4 g/dL | ↑1-year cardiac mortality |
 Gopal et al. [67] | 2010 | 2907 | Aged 70–79 years without HF | < 4.0 g/dl | ↑6-year HF risk but the risk declined annually |
 Filippatos et al. [68] | 2011 | 5450 | Aged ≥65 years, without HF | ≤ 3.5 mg/dL | ↑10-year HF incidence |
 Liu et al. [62] | 2012 | 576 | Acute HF, preserved EF | ≤ 3.4 g/dl | ↑1-year all mortality |
 Polat et al. [65] | 2014 | 135 | Acute, systolic HF | < 3.1 g/dL | ↑1-year mortality |
 Bonilla-Palomas et al. [66] | 2014 | 362 | Acute HF | ≤ 3.4 g/dL | ↑In-hospital and 1-year all mortality |